gross profit bridgeinconsistent2022-03-31
Withheld: gross profit could not be reconciled with the rest of this filer’s statement.
Revenue
$100.00M
Fiscal year ended 2022-03-31Operating income
-$15.59M
Fiscal year ended 2022-03-31Free cash flow
Unavailable
Fiscal year ended 2022-03-31Grace Therapeutics, Inc. (GRCE) reported revenue of $100.00M and net income of -$9.82M for the fiscal year ended 2022-03-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from Grace Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2022-03-31 | 2021-03-31 |
|---|---|---|
| Revenue | $100.00M | $196.00K |
| Cost of revenue | $0 | $76.00K |
| Gross profit | Unavailable | $120.00K |
| Operating income | -$15.59M | -$16.42M |
| Net income | -$9.82M | -$19.68M |
| Research & development | $5.56M | $4.17M |
| Weighted-average diluted shares | shares 36.84M | Unavailable |
| Pretax income | -$10.47M | -$19.68M |
| Income tax expense | -$648.00K | $0 |
| Diluted EPS | $-0.27 | Unavailable |
| Selling, general & administrative | $9.78M | $6.66M |
| General & administrative | $9.26M | $5.52M |
| Selling & marketing | $518.00K | $1.14M |
Balance
| Metric | 2022-03-31 | 2021-03-31 |
|---|---|---|
| Cash & equivalents | $30.34M | $50.94M |
| Total assets | $128.62M | $62.46M |
| Current assets | $45.28M | $62.37M |
| Total liabilities | $20.35M | $6.80M |
| Current liabilities | $3.26M | $1.58M |
| Total equity incl. NCI | $108.27M | $55.66M |
| Temporary (mezzanine) equity | Unavailable | Unavailable |
| Inventory | Unavailable | Unavailable |
| Accounts receivable | $548.00K | $530.00K |
| Goodwill | $12.96M | Unavailable |
| Long-term debt | Unavailable | Unavailable |
| Accounts payable | Unavailable | Unavailable |
Cash flow
| Metric | 2022-03-31 | 2021-03-31 |
|---|---|---|
| Operating cash flow | -$17.23M | -$14.32M |
| Capital expenditures | Unavailable | Unavailable |
| Investing cash flow | -$3.52M | -$9.86M |
| Financing cash flow | $0 | $59.49M |
| Net change in cash | -$20.60M | $36.70M |
| Stock-based compensation | $1.34M | $1.17M |
| Common dividends paid | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable |
| Depreciation & amortization | Unavailable | Unavailable |
Derived
| Metric | 2022-03-31 | 2021-03-31 |
|---|---|---|
| Free cash flow | Unavailable | Unavailable |
| Gross margin | Unavailable | 61.2% |
| Operating margin | -15.6% | -8377.0% |
| FCF margin | Unavailable | Unavailable |
| SBC / revenue | 1.3% | 599.0% |
| Current ratio | 13.89x | 39.50x |
| Revenue YoY growth | 50920.4% | Unavailable |
| Net margin | -9.8% | -10039.8% |
| R&D / revenue | 5.6% | 2129.1% |
| CapEx / revenue | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GRCE in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-13View SEC filing
10-K · Filed 2026-06-18View SEC filing
10-Q · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-K · Filed 2025-06-23View SEC filing
Reconciliation checks needing review
2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
cash flow reconciliationreview2021-03-31
Operating, investing and financing flows differ from the reported change in cash by 6329000, beyond tolerance 1000000.